{"id":32273,"date":"2025-04-23T14:57:38","date_gmt":"2025-04-23T06:57:38","guid":{"rendered":"https:\/\/flcube.com\/?p=32273"},"modified":"2025-04-23T14:57:39","modified_gmt":"2025-04-23T06:57:39","slug":"novocure-wins-ce-mark-for-optune-lua-in-metastatic-nsclc-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32273","title":{"rendered":"Novocure Wins CE Mark for Optune Lua in Metastatic NSCLC Treatment"},"content":{"rendered":"\n

Switzerland-based Novocure (NASDAQ: NVCR<\/a>), the developer of Tumor Treating Fields (TTFields) for cancer therapy, has announced CE mark approval for its Optune Lua device. This wearable technology is now approved for use in adult patients with metastatic non-small cell lung cancer (NSCLC) who have progressed after platinum-based treatment and are receiving immune checkpoint inhibitors or docetaxel.<\/p>\n\n\n\n

Optune Lua: Mechanism and Innovation<\/strong>
Optune Lua delivers TTFields through non-invasive, wearable arrays. These alternating electric fields disrupt cancer cell division, leading to cell death while minimizing impact on healthy cells. The device received FDA approval in the US in October 2024 and has now secured CE mark recognition in the EU.<\/p>\n\n\n\n

Clinical Evidence and Impact<\/strong>
The CE mark approval is supported by the Phase III LUNAR study, which demonstrated improved median overall survival (OS) of 13.2 months for patients treated with Optune Lua in combination with immune checkpoint inhibitors or docetaxel, compared to 9.9 months for those receiving only the latter therapies. This advancement offers a new therapeutic option for patients with metastatic NSCLC.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Switzerland-based Novocure (NASDAQ: NVCR), the developer of Tumor Treating Fields (TTFields) for cancer therapy, has…<\/p>\n","protected":false},"author":1,"featured_media":32274,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,22],"tags":[16,1321,1322,15],"class_list":["post-32273","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-medical-device","tag-cancer","tag-nasdaq-nvcr","tag-novocure","tag-product-approvals"],"yoast_head":"\nNovocure Wins CE Mark for Optune Lua in Metastatic NSCLC Treatment - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Switzerland-based Novocure (NASDAQ: NVCR), the developer of Tumor Treating Fields (TTFields) for cancer therapy, has announced CE mark approval for its Optune Lua device. This wearable technology is now approved for use in adult patients with metastatic non-small cell lung cancer (NSCLC) who have progressed after platinum-based treatment and are receiving immune checkpoint inhibitors or docetaxel.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32273\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novocure Wins CE Mark for Optune Lua in Metastatic NSCLC Treatment\" \/>\n<meta property=\"og:description\" content=\"Switzerland-based Novocure (NASDAQ: NVCR), the developer of Tumor Treating Fields (TTFields) for cancer therapy, has announced CE mark approval for its Optune Lua device. This wearable technology is now approved for use in adult patients with metastatic non-small cell lung cancer (NSCLC) who have progressed after platinum-based treatment and are receiving immune checkpoint inhibitors or docetaxel.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32273\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-23T06:57:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-23T06:57:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2306.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32273#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32273\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novocure Wins CE Mark for Optune Lua in Metastatic NSCLC Treatment\",\"datePublished\":\"2025-04-23T06:57:38+00:00\",\"dateModified\":\"2025-04-23T06:57:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32273\"},\"wordCount\":183,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32273#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2306.webp\",\"keywords\":[\"Cancer\",\"NASDAQ: NVCR\",\"Novocure\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Medical Device\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32273#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32273\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32273\",\"name\":\"Novocure Wins CE Mark for Optune Lua in Metastatic NSCLC Treatment - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32273#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32273#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2306.webp\",\"datePublished\":\"2025-04-23T06:57:38+00:00\",\"dateModified\":\"2025-04-23T06:57:39+00:00\",\"description\":\"Switzerland-based Novocure (NASDAQ: NVCR), the developer of Tumor Treating Fields (TTFields) for cancer therapy, has announced CE mark approval for its Optune Lua device. This wearable technology is now approved for use in adult patients with metastatic non-small cell lung cancer (NSCLC) who have progressed after platinum-based treatment and are receiving immune checkpoint inhibitors or docetaxel.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32273#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32273\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32273#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2306.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2306.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novocure Wins CE Mark for Optune Lua in Metastatic NSCLC Treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32273#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novocure Wins CE Mark for Optune Lua in Metastatic NSCLC Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novocure Wins CE Mark for Optune Lua in Metastatic NSCLC Treatment - Insight, China's Pharmaceutical Industry","description":"Switzerland-based Novocure (NASDAQ: NVCR), the developer of Tumor Treating Fields (TTFields) for cancer therapy, has announced CE mark approval for its Optune Lua device. This wearable technology is now approved for use in adult patients with metastatic non-small cell lung cancer (NSCLC) who have progressed after platinum-based treatment and are receiving immune checkpoint inhibitors or docetaxel.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32273","og_locale":"en_US","og_type":"article","og_title":"Novocure Wins CE Mark for Optune Lua in Metastatic NSCLC Treatment","og_description":"Switzerland-based Novocure (NASDAQ: NVCR), the developer of Tumor Treating Fields (TTFields) for cancer therapy, has announced CE mark approval for its Optune Lua device. This wearable technology is now approved for use in adult patients with metastatic non-small cell lung cancer (NSCLC) who have progressed after platinum-based treatment and are receiving immune checkpoint inhibitors or docetaxel.","og_url":"https:\/\/flcube.com\/?p=32273","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-23T06:57:38+00:00","article_modified_time":"2025-04-23T06:57:39+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2306.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32273#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32273"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novocure Wins CE Mark for Optune Lua in Metastatic NSCLC Treatment","datePublished":"2025-04-23T06:57:38+00:00","dateModified":"2025-04-23T06:57:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32273"},"wordCount":183,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32273#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2306.webp","keywords":["Cancer","NASDAQ: NVCR","Novocure","Product approvals"],"articleSection":["Company","Medical Device"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32273#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32273","url":"https:\/\/flcube.com\/?p=32273","name":"Novocure Wins CE Mark for Optune Lua in Metastatic NSCLC Treatment - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32273#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32273#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2306.webp","datePublished":"2025-04-23T06:57:38+00:00","dateModified":"2025-04-23T06:57:39+00:00","description":"Switzerland-based Novocure (NASDAQ: NVCR), the developer of Tumor Treating Fields (TTFields) for cancer therapy, has announced CE mark approval for its Optune Lua device. This wearable technology is now approved for use in adult patients with metastatic non-small cell lung cancer (NSCLC) who have progressed after platinum-based treatment and are receiving immune checkpoint inhibitors or docetaxel.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32273#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32273"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32273#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2306.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2306.webp","width":1080,"height":608,"caption":"Novocure Wins CE Mark for Optune Lua in Metastatic NSCLC Treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32273#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novocure Wins CE Mark for Optune Lua in Metastatic NSCLC Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2306.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32273","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32273"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32273\/revisions"}],"predecessor-version":[{"id":32275,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32273\/revisions\/32275"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32274"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32273"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32273"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32273"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}